Dr. Ketaren headed the Laboratory of Biochemistry and Structural biology this year, and introduced her group of budding young scientists to a major technological strength of the NCDIR, single chain antibody variants, termed Nanobodies. The aim of Dr. Ketaren’s group at the school was to explore the properties of Nanobodies that make them such versatile reagents in biomedicine and general science.
Dr. LaCava, with Dr. Thomas Widmann from GENyO Pfizer-University of Granada ran the Laboratory of Transposable elements. They were testing the effects of drugs on the transposition rate of the transposable element Line-1 (L1) in HeLa cells alongside testing some recently made nanobodies targeting L1 RNPs using immunoprecipitation assays.
The findings of both labs were presented at a conference held at the Biology Campus of AMU. It’s the 3rd year in a row both Dr. LaCava and Dr. Ketaren have participated in running labs at the school. In addition to running their research labs, both Drs participated in running a course, teaching students various aspects of the path to developing therapeutics. Additionally Dr. Ketaren presented a lecture open to the entire university, discussing the future of nanobody technology in medicine. Such work by our members underscores one of the major goals of the NCDIR, to share the findings of our research to the global scientific community and to teach others how to use the technologies developed and matured by our Center.